Clene Inc. - Press Releases

Year

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8 ® in the RESCUE ALS open-label extension trial Reported statistically significant long-term survival benefit of 70% decreased risk of death

November 7, 2023

PDF Version

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Funding to Support Research and Expanded Access of Investigational Drug in ALS SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a

October 5, 2023

PDF Version

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine

September 28, 2023

PDF Version

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to

September 25, 2023

PDF Version

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 ® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046 Prolonged life with 59% decreased risk of death for participants in an integrated meta-analysis across

September 25, 2023

PDF Version

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to

August 30, 2023

PDF Version

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

19.3 month significant survival difference for CNM-Au8 ® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au 8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug.

August 29, 2023

PDF Version

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8 ® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and its open-label

August 14, 2023

PDF Version

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today

August 2, 2023

PDF Version

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary

June 26, 2023

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28